APSR2026-239

 
Late-Breaking
Submitted
Poster Presentation
 
AP14-007
P26
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1203775-46904-AP14-007 APSR26_Poster Template_425782.pdf
Format: PDF Only
08. Lung Cancer
5

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Kejing Yang * Tianjin Medical University General Hospital Medical Oncology Department Tianjin China
Xin Wang - Tianjin Medical University General Hospital Medical Oncology Department Tianjin China
Tao Yu - Tianjin Medical University General Hospital Medical Oncology Department Tianjin China
Diansheng Zhong - Tianjin Medical University General Hospital Medical Oncology Department Tianjin China
Linlin Zhang - Tianjin Medical University General Hospital Medical Oncology Department Tianjin China
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Kejing
Yang
yangkjyj@163.com
+8618988201298
31-40
China
Original Research
The Diagnostic Journey of Lung Cancer with Co-existing Pancreatic Lesions: A Triad of Distinct Outcomes
Maximum 25 words
Abstract Content
When lung and pancreatic tumors coexist, determining whether the lesions are primary or metastatic poses a significant challenge, as it directly influences subsequent treatment selection. This study presents three definitively diagnosed cases to elucidate this diagnostic process.
We retrospectively analyzed three patients with tumors in both the lung and pancreas detected on imaging. The primary origin remained indeterminate after immunohistochemistry (IHC). We therefore employed multidisciplinary team (MDT) discussion and molecular profiling (90-gene assay or next-generation sequencing (NGS) to distinguish the tissue origin.
Case 1: IHC staining confirmed neuroendocrine tumors at both sites but could not identify the primary. 90-gene assay and NGS redirected the diagnosis to primary pancreatic neuroendocrine carcinoma with lung metastasis, finalized by MDT consensus. Case 2: Histopathology and concordant NGS results (KRAS p.G12C mutation at both sites) indicated pulmonary small cell neuroendocrine carcinoma with pancreatic metastasis. However, discordant responses to systemic therapy created diagnostic uncertainty. MDT discussion and a subsequent 90-gene assay of the pancreatic lesion ultimately affirmed the lung origin. Case 3: The patient was diagnosed with ALK-fusion lung adenocarcinoma. Upon pancreatic progression, biopsy revealed a morphologically and molecularly distinct adeno-squamous carcinoma (KRAS/TP53 mutations). Although the 90-gene assay suggested a breast origin, subsequent breast imaging was negative. After MDT discussion, a definitive primary site remained elusive, resulting in a diagnosis of primary lung adenocarcinoma and cancer of unknown primary (adeno-squamous carcinoma).
When conventional imaging and pathology are insufficient to determine the tumors of uncertain origin, a combined approach of molecular diagnostics and MDT review is essential to establish the diagnosis and guide therapy selection.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Lung Cancer, Pancreatic Tumor, Diagnosis
maximum 3 keywords and no abbreviations, separated by commas
 
260